



Representative Legal Matters

Paul Johnson

- Advised a technology company in opposing Microsoft's USD 69 billion acquisition of Activision Blizzard, and was involved in the first ever 'Phase III' at the UK CMA.
- Advised a technology company in opposing the proposed USD 40 billion acquisition of Arm by Nvidia, which was abandoned.
- Advised Hitachi in relation to its approximately USD 11 billion acquisition of ABB's power grid business.
- Advised Nielsen Holdings on its approximately USD 10 billion sale to a Buyers Consortia.
- Advised Abbott Laboratories on its USD 5.8 billion acquisition of Alere, Inc. and successfully negotiated an upfront remedy with the European Commission to obtain extended phase I clearance.
- Advised Galapagos NV on its approximately USD 5.1 collaboration with Gilead Sciences Inc.
- Advised Bayer AG on its acquisition of Asklepios BioPharmaceutical, Inc. for approximately USD 4 billion.
- Advised a medical device manufacturer on its sale to a medical device manufacturer for approximately USD 3.0 billion
- Advised Jin Jiang on its acquisition of Radisson for approximately USD 2 billion.
- Advised Lonza acquisition of Capsugel for approximately USD 5.5 billion.
- Advised the Nielsen Company on its sale of Nielsen IQ to Advent International for USD 2.7 billion.
- Advised H. Lundbeck A/S on its approximately USD 1.95 billion acquisition of Alder BioPharmaceuticals.
- Advised Varian in relation to its proposed USD 1.5-billion merger, and successfully negotiated an upfront remedy with the European Commission to obtain extended phase I clearance.
- Advised GSK on the USD 500 million divestments of its cephalosporin business (global) and related manufacturing and supply arrangements.
- Advised GSK on the disposal of its API manufacturing site in Cork, Ireland.
- Advised GSK on the disposal of its manufacturing facilities in Verona, Italy to ACS Dobfar.



- Advised a global pharmaceutical company in the antitrust aspects of a USD 400 million acquisition of a biopharmaceutical company.
- Advised a global leader in the digital product market in connection with an acquisition of an online course creation and sales platform.
- Advised GSK on the disposal of a prescription drug indicated for the emergency treatment of epileptic children with prolonged acute convulsive seizures to a European leader in pharmaceutical products.
- Advised Lonza and Chr. Hansen in their microbiome joint venture before the European Commission.
- Advised a global music streaming company on the UK CMA's market study into music streaming.
- Advised a global technology company on cloud market studies in France, Japan, the Netherlands and Korea.
- Advised Warner Bros. in the European Commission's investigation into cross-border access to pay-TV content (case AT.40023), and successfully negotiated a settlement agreement with the case team.
- Advised a payment scheme in a variety of regulatory issues, including dealing with national banks and EU regulations in the payment sector, including the AML directive, PSDII, the Interchange Fee Regulation and the ECB's proposal on cyber resilience.
- Advised a major global financial institution in relation to a number of investigations concerning potentially collusive behavior.
- Advised a major global insurance institution on Brexit and developed options to ensure continued access to the EU single market.
- Advised a major insurance company in the London market dry run that tested the resilience of the world's pre-eminent insurance market on a major loss event.